Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VCEL
HOLDVericel Corporation · Healthcare · United States · $2.3B · Avg Vol: $29M/d
COMPANY DESCRIPTION
Vericel Corporation is a commercial-stage biotechnology company specializing in advanced autologous cell therapies for severe medical conditions, primarily focusing on knee cartilage repair (MACI) and burn care (Epicel, NexoBrid). The company maintains a leading position in these niche markets due to its proprietary manufacturing processes, strong clinical evidence, and the high regulatory barriers inherent in cell therapy. Vericel acts as a pioneer in regenerative medicine with a highly specialized product portfolio.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 164.4M | 197.5M | 237.2M | 276.3M | 18.9% | 292.1M | 332.2M | 388.7M | 18.6% |
| EPS | -0.16 | -0.35 | -0.07 | 0.21 | 0.33 | 57.1% | 0.42 | 0.47 | — | 41.3% |
| Shares | — | 47.3M | 47.8M | 49.6M | 50.6M | +7.1% | 51.1M | — | — | — |
| Debt | — | 47.6M | 88.0M | 99.0M | 96.4M | 26.5% | 95.0M | — | — | — |
| Equity | — | 192.3M | 226.0M | 292.0M | 354.6M | 22.6% | — | — | — | — |
| Op CF | — | 17.7M | 35.3M | 58.2M | 51.9M | 43.2% | 61.7M | — | — | — |
| Inv CF | — | -36.2M | -3.1M | -79.0M | -43.9M | — | — | — | — | — |
| Fin CF | — | 1.0M | 3.6M | 19.1M | 7.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VCEL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VCEL | Vericel Corporation(you) | $2.3B | 65 | HOLD |
| FTRE | Fortrea Holdings Inc. | $1.8B | 58 | HOLD |
| ACAD | ACADIA Pharmaceuticals Inc. | $4.3B | 62 | HOLD |
| URGN | UroGen Pharma Ltd. | $2.0B | 48 | HOLD |
| MRVI | Maravai LifeSciences Holdings, Inc. | $2.5B | 42 | HOLD |
| ANAB | AnaptysBio, Inc. | $1.6B | 47 | HOLD |
| 0I3Q.L | Corcept Therapeutics Incorporated | $5.7B | 73 | BUY |
| 0JDK.L | Iovance Biotherapeutics, Inc. | $638M | 64 | HOLD |
| LGND | Ligand Pharmaceuticals Incorporated | $6.0B | 74 | BUY |
| SLS | SELLAS Life Sciences Group, Inc. | $2.2B | 37 | HOLD |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%